Infliximab and tofacitinib attenuate neutralizing antibody responses against SARS-CoV-2 ancestral and Omicron variants in IBD patients following 3 doses of COVID-19 vaccine

Posted on October 18, 2022 by Gastroenterology Journal
This entry was posted in News. Bookmark the permalink.